ClinicalTrials.gg
CompletedNCT01082081Updated May 13, 2015Results posted

Post-operative Dental Pain Study Comparing Analgesic Efficacy

A Phase 4 interventional study of Paracetamol 1000 mg and Paracetamol 500 mg in Post-surgical Dental Pain, sponsored by GlaxoSmithKline. Completed at 2 sites in United States. Open to participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2015-05-13.

Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 55 studies in Toothache with a site in United States — 7 open to participants now, 7 under way, none of them phase 3. Toothache · United States.

Enrollment
11th of 51
300 · median 193
Started
2009
with 9 others
Phase 4
10 of 55
1 open now
Registered
15th of 55
by date
Lead sponsor
5 of 55
GlaxoSmithKline

Among the 55 studies in Toothache with a site in United States, this one is the 11th largest by enrollment of the 51 interventional ones that give a count, is one of 10 that started in 2009, is one of 10 in phase 4, and was the 15th registered.

Toothache

143 studies on the registry are indexed under Toothache; 29 are open to participants now.

Browse Toothache studies →

Open to participants now

7 of the 55 studies in Toothache with a site in United States are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 15 Toothache studies recruiting now, 4 (27%) set no upper age limit and 11 (73%) stop at 75 or younger; 7 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies in Toothache with a site in United States, or all of them as a file.
02

Study summary

GlaxoSmithKline will be conducting this trial to compare analgesics efficacy of paracetamol 1000mg vs 500mg . The post-surgical dental pain model will be used to evaluate the analgesic efficacy of paracetamol. Each subject will be enrolled in the study for up to six weeks. The duration of the entire study will be approximately 16 weeks. Each subject will have to come to the clinic for three visits (Screening, Treatment and Follow up visits).

03

Conditions studied

  • Post-surgical Dental Pain

Browse trials for

Keywords

  • paracetamol
  • dental pain
  • Post-surgical dental pain
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Subjects aged 18-45 years with moderate-to-severe dental pain assessed by verbal rating scale (VRS) and confirmed by a score of at least 50 mm out of 100 mm using a visual analogue scale (VAS) following surgical removal of third molars, of which at least one has to be a mandibular partially bony or full bony impaction.
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
300 participants (actual)

Study arms

  • Experimental
    Paracetamol 1000 mg

    Paracetamol 1000 mg

    Drug: Paracetamol 1000 mg

  • Experimental
    Paracetamol 500 mg

    Paracetamol 500 mg

    Drug: Paracetamol 500 mg

  • Placebo comparator
    Placebo

    Placebo

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Sum of Pain Relief and Pain Intensity Differences From 0 to 6 Hours (SPRID 6 Hours)

    SPRID:Sum of Pain Intensity Difference (SPID) and Total Pain Relief (TOTPAR) at each post-dosing time-point. SPRID score ranged from -5.8 (least pain relief) to 40.3 (highest pain relief). SPID and TOTPAR were calculated as weighted sums of Pain Intensity Differences (PID) and Pain Relief Scores (PRS) at each measurement time, respectively. PID was derived by subtracting the pain severity score at a given post-dosing time-point from the baseline \[pain severity score range:0-no pain, 1-mild pain, 2-moderate pain, 3-severe pain using a 4-point categorical Verbal Rating Scale (VRS)\]. If the subject rated pain intensity as 2 or 3, pain was assessed using a 100 mm Visual Analog Scale (VAS) \[0 (no pain), 100 (worst pain)\]. VAS scores were converted into PID scores by subtracting them from baseline pain scores. PRS was assessed on 5-point categorical pain relief rating scale \[0-no relief, 1-little relief, 2-some relief, 3-a lot of relief, 4-complete relief\]

    Time frame: Every two hours from baseline to 6 hours post dose

Secondary outcomes

  1. Time to Confirmed First Perceptible Pain Relief

    Participants recorded the time to first perceptible relief by starting the first stopwatch at the time of dosing and stopping it when he/she experienced the first perceptible pain relief. The first perceptible pain relief was confirmed if the participant also stopped the second stopwatch indicating meaningful relief.

    Time frame: Baseline to 6 hours post dose

  2. Time to Onset of Meaningful Pain Relief

    Participants evaluated the time to meaningful relief by stopping a second stopwatch when they first began to experience meaningful relief.

    Time frame: Baseline to 6 hours post dose

  3. Time to Start Using Rescue Medication

    Median time of use of rescue medication by participants was calculated.

    Time frame: Baseline to 6 hours post dose

  4. Percentage of Participants Who Took Rescue Medication Within 2 Hours

    Percentage of participants who received rescue medication within 2 hours

    Time frame: Baseline to 2 hours post dose

  5. Percentage of Participants Who Took Rescue Medication During 2 to 6 Hours

    Percentage of participants who took rescue medication during 2 to 6 hours

    Time frame: Within 2 to 6 hours post dose

  6. SPRID at 2 Hours

    SPRID:Sum of Pain Intensity Difference (SPID) and Total Pain Relief (TOTPAR) at each post-dosing time-point. SPRID score ranged from -1.8 (least pain relief) to 12.3 (highest pain relief). SPID and TOTPAR were calculated as weighted sums of Pain Intensity Differences (PID) and Pain Relief Scores (PRS) at each measurement time, respectively. PID was derived by subtracting the pain severity score at a given post-dosing time-point from the baseline \[pain severity score range:0-no pain, 1-mild pain, 2-moderate pain, 3-severe pain using a 4-point categorical Verbal Rating Scale (VRS)\]. If the subject rated pain intensity as 2 or 3, pain was assessed using a 100 mm Visual Analog Scale (VAS) \[0 (no pain), 100 (worst pain)\]. VAS scores were converted into PID scores by subtracting them from baseline pain scores. PRS was assessed on 5-point categorical pain relief rating scale \[0-no relief, 1-little relief, 2-some relief, 3-a lot of relief, 4-complete relief\]

    Time frame: Every two hours from baseline to 2 hours post dose

  7. SPRID at 4 Hours

    SPRID:Sum of Pain Intensity Difference (SPID) and Total Pain Relief (TOTPAR) at each post-dosing time-point. SPRID score ranged from -3.8 (least pain relief) to 26.3 (highest pain relief). SPID and TOTPAR were calculated as weighted sums of Pain Intensity Differences (PID) and Pain Relief Scores (PRS) at each measurement time, respectively. PID was derived by subtracting the pain severity score at a given post-dosing time-point from the baseline \[pain severity score range:0-no pain, 1-mild pain, 2-moderate pain, 3-severe pain using a 4-point categorical Verbal Rating Scale (VRS)\]. If the subject rated pain intensity as 2 or 3, pain was assessed using a 100 mm Visual Analog Scale (VAS) \[0 (no pain), 100 (worst pain)\]. VAS scores were converted into PID scores by subtracting them from baseline pain scores. PRS was assessed on 5-point categorical pain relief rating scale \[0-no relief, 1-little relief, 2-some relief, 3-a lot of relief, 4-complete relief\]

    Time frame: Every two hours from baseline to 4 hours post dose

  8. Total Pain Relief (TOTPAR) at 2 Hours

    TOTPAR was calculated as sum of products of pain relief (PR) at a given time-point (t) with the time-interval from that time-point to the previous time-point (t-1). The time-intervals used were 0-15, 15-30, 30-45, 45-60, 60-90, 90-120. Higher score indicated greater pain relief. TOTPARt = ∑PR x (timet - timet-1). PR score was assessed at each of the above time-points based on a 5-point categorical scale \[0-no relief, 1-little relief, 2-meaningful relief, 3-a lot of relief, 4-complete relief\].

    Time frame: Every two hours from baseline to 2 hours post dose

  9. TOTPAR at 4 Hours

    TOTPAR was calculated as sum of products of pain relief (PR) at a given time-point (t) with the time-interval from that time-point to the previous time-point (t-1). The time-intervals used were 0-15, 15-30, 30-45, 45-60, 60-90, 90-120, 120-240. Higher score indicated greater pain relief. TOTPARt = ∑PR x (timet - timet-1). PR score was assessed at each of the above time-points based on a 5-point categorical scale \[0-no relief, 1-little relief, 2-meaningful relief, 3-a lot of relief, 4-complete relief\].

    Time frame: Every two hours from baseline to 4 hours post dose

  10. TOTPAR at 6 Hours

    TOTPAR was calculated as sum of products of pain relief (PR) at a given time-point (t) with the time-interval from that time-point to the previous time-point (t-1). The time-intervals used were 0-15, 15-30, 30-45, 45-60, 60-90, 90-120, 120-240, 240-300 and 300-360. Higher score indicated greater pain relief. TOTPARt = ∑PR x (timet - timet-1). PR score was assessed at each of the above time-points based on a 5-point categorical scale \[0-no relief, 1-little relief, 2-meaningful relief, 3-a lot of relief, 4-complete relief\].

    Time frame: Every two hours from baseline to 6 hours post dose

  11. Sum of Pain Intensity Difference (SPID) Scores at 2 Hours

    SPID was calculated as sum of products of Pain Intensity Differences (PID) at a given time-point (t) with the time-interval from that time-point to the previous time-point (t-1). The time-intervals used were 0-15, 15-30, 30-45, 45-60, 60-90, 90-120. Positive and higher scores indicate greater reduction in pain. SPIDt = ∑PID x (timet - timet-1) Pain Intensity was assessed at baseline and at each time-point based on a 4-point categorical Verbal Rating Scale (VRS) scale: 0-no pain, 1-mild pain, 2-moderate pain, 3-severe pain. If the subject rated pain intensity as "2" or "3", pain was assessed using a 100 mm Visual Analog Scale (VAS) \[0 (no pain), 100 (worst pain)\]. VAS scores were converted into PID scores by subtracting them from pain scores taken at baseline.

    Time frame: Every two hours from baseline to 2 hours post dose

  12. SPID Scores at 4 Hours

    SPID was calculated as sum of products of Pain Intensity Differences (PID) at a given time-point (t) with the time-interval from that time-point to the previous time-point (t-1). The time-intervals used were 0-15, 15-30, 30-45, 45-60, 60-90, 90-120, 120-240. Positive and higher scores indicate greater reduction in pain. SPIDt = ∑PID x (timet - timet-1) Pain Intensity was assessed at baseline and at each time-point based on a 4-point categorical Verbal Rating Scale (VRS) scale: 0-no pain, 1-mild pain, 2-moderate pain, 3-severe pain. If the subject rated pain intensity as "2" or "3", pain was assessed using a 100 mm Visual Analog Scale (VAS) \[0 (no pain), 100 (worst pain)\]. VAS scores were converted into PID scores by subtracting them from pain scores taken at baseline.

    Time frame: Every two hours from baseline to 4 hours post dose

  13. SPID Scores at 6 Hours

    SPID was calculated as sum of products of Pain Intensity Differences (PID) at a given time-point (t) with the time-interval from that time-point to the previous time-point (t-1). The time-intervals used were 0-15, 15-30, 30-45, 45-60, 60-90, 90-120, 120-240, 240-300 and 300-360. Positive and higher scores indicate greater reduction in pain. SPIDt = ∑PID x (timet - timet-1) Pain Intensity was assessed at baseline and at each time-point based on a 4-point categorical Verbal Rating Scale (VRS) scale: 0-no pain, 1-mild pain, 2-moderate pain, 3-severe pain. If the subject rated pain intensity as "2" or "3", pain was assessed using a 100 mm Visual Analog Scale (VAS) \[0 (no pain), 100 (worst pain)\]. VAS scores were converted into PID scores by subtracting them from pain scores taken at baseline.

    Time frame: Every two hours from baseline to 6 hours post dose

  14. Participants Global Assessment to Response to Treatment (PGART)

    PGART was measured by a score in a scale from 0-4: 0- Poor; 1- Fair 2- Good; 3- Very Good; 4- Excellent.

    Time frame: Baseline to 6 hours post dose

07

Results

Posted Jan 22, 2015

Participant flow

Participants were recruited at the clinical site.

Participant flow — Overall Study
MilestoneParacetamol Caplet 1000 Milligrams (mg)Paracetamol Caplet 500 mgPlacebo Caplet
Started12111960
Completed12111858
Not completed012
Withdrew: Lost to follow-up001
Withdrew: Withdrawal by subject001
Withdrew: Other reason010

Outcome measures

PrimarySum of Pain Relief and Pain Intensity Differences From 0 to 6 Hours (SPRID 6 Hours)

SPRID:Sum of Pain Intensity Difference (SPID) and Total Pain Relief (TOTPAR) at each post-dosing time-point. SPRID score ranged from -5.8 (least pain relief) to 40.3 (highest pain relief). SPID and TOTPAR were calculated as weighted sums of Pain Intensity Differences (PID) and Pain Relief Scores (PRS) at each measurement time, respectively. PID was derived by subtracting the pain severity score at a given post-dosing time-point from the baseline \[pain severity score range:0-no pain, 1-mild pain, 2-moderate pain, 3-severe pain using a 4-point categorical Verbal Rating Scale (VRS)\]. If the subject rated pain intensity as 2 or 3, pain was assessed using a 100 mm Visual Analog Scale (VAS) \[0 (no pain), 100 (worst pain)\]. VAS scores were converted into PID scores by subtracting them from baseline pain scores. PRS was assessed on 5-point categorical pain relief rating scale \[0-no relief, 1-little relief, 2-some relief, 3-a lot of relief, 4-complete relief\]

Time frame:
Every two hours from baseline to 6 hours post dose
Reported as:
Mean · Units on a scale
Sum of Pain Relief and Pain Intensity Differences From 0 to 6 Hours (SPRID 6 Hours)
Units on a scaleParacetamol Caplet 1000 mgParacetamol Caplet 500 mgPlacebo Caplet
Sum of Pain Relief and Pain Intensity Differences From 0 to 6 Hours (SPRID 6 Hours)10.60 ± 11.755.87 ± 9.033.35 ± 9.67
Statistical analysis
  • Paracetamol Caplet 1000 mg vs Paracetamol Caplet 500 mg · ANCOVA · p = 0.0004 · Adjusted mean difference: 4.77 · 95% CI 2.15 to 7.39Difference is first named treatment minus second named treatment such that a positive difference favors the first named treatment.
  • Paracetamol Caplet 1000 mg vs Placebo Caplet · ANCOVA · p = <0.0001 · Adjusted mean difference: 7.25 · 95% CI 4.04 to 10.45Difference was first named treatment minus second named treatment such that a positive difference favors the first named treatment.
  • Paracetamol Caplet 500 mg vs Placebo Caplet · ANCOVA · p = 0.1307 · Adjusted mean difference: 2.48 · 95% CI -0.74 to 5.69Difference is first named treatment minus second named treatment such that a positive difference favors the first named treatment.
SecondaryTime to Confirmed First Perceptible Pain Relief

Participants recorded the time to first perceptible relief by starting the first stopwatch at the time of dosing and stopping it when he/she experienced the first perceptible pain relief. The first perceptible pain relief was confirmed if the participant also stopped the second stopwatch indicating meaningful relief.

Time frame:
Baseline to 6 hours post dose
Reported as:
Mean · minutes
Time to Confirmed First Perceptible Pain Relief
minutesParacetamol Caplet 1000 mgParacetamol Caplet 500 mgPlacebo Caplet
Time to Confirmed First Perceptible Pain Relief80.63 ± 132.65119.10 ± 156.44189.53 ± 172.28
SecondaryTime to Onset of Meaningful Pain Relief

Participants evaluated the time to meaningful relief by stopping a second stopwatch when they first began to experience meaningful relief.

Time frame:
Baseline to 6 hours post dose
Reported as:
Mean · minutes
Time to Onset of Meaningful Pain Relief
minutesParacetamol Caplet 1000 mgParacetamol Caplet 500 mgPlacebo Caplet
Time to Onset of Meaningful Pain Relief96.44 ± 128.64129.75 ± 150.38207.67 ± 162.01
SecondaryTime to Start Using Rescue Medication

Median time of use of rescue medication by participants was calculated.

Time frame:
Baseline to 6 hours post dose
Reported as:
Median · minutes
Time to Start Using Rescue Medication
minutesParacetamol Caplet 1000 mgParacetamol Caplet 500 mgPlacebo Caplet
Time to Start Using Rescue Medication242.00 (92.00 to 360.00)189.00 (65.00 to 360.00)148.00 (61.00 to 360.00)
SecondaryPercentage of Participants Who Took Rescue Medication Within 2 Hours

Percentage of participants who received rescue medication within 2 hours

Time frame:
Baseline to 2 hours post dose
Reported as:
Number · Percentage of participants
Percentage of Participants Who Took Rescue Medication Within 2 Hours
Percentage of participantsParacetamol Caplet 1000 mgParacetamol Caplet 500 mgPlacebo Caplet
Percentage of Participants Who Took Rescue Medication Within 2 Hours5.0011.8018.30
SecondaryPercentage of Participants Who Took Rescue Medication During 2 to 6 Hours

Percentage of participants who took rescue medication during 2 to 6 hours

Time frame:
Within 2 to 6 hours post dose
Reported as:
Number · Percentage of participants
Percentage of Participants Who Took Rescue Medication During 2 to 6 Hours
Percentage of participantsParacetamol Caplet 1000 mgParacetamol Caplet 500 mgPlacebo Caplet
Percentage of Participants Who Took Rescue Medication During 2 to 6 Hours57.955.553.3
SecondarySPRID at 2 Hours

SPRID:Sum of Pain Intensity Difference (SPID) and Total Pain Relief (TOTPAR) at each post-dosing time-point. SPRID score ranged from -1.8 (least pain relief) to 12.3 (highest pain relief). SPID and TOTPAR were calculated as weighted sums of Pain Intensity Differences (PID) and Pain Relief Scores (PRS) at each measurement time, respectively. PID was derived by subtracting the pain severity score at a given post-dosing time-point from the baseline \[pain severity score range:0-no pain, 1-mild pain, 2-moderate pain, 3-severe pain using a 4-point categorical Verbal Rating Scale (VRS)\]. If the subject rated pain intensity as 2 or 3, pain was assessed using a 100 mm Visual Analog Scale (VAS) \[0 (no pain), 100 (worst pain)\]. VAS scores were converted into PID scores by subtracting them from baseline pain scores. PRS was assessed on 5-point categorical pain relief rating scale \[0-no relief, 1-little relief, 2-some relief, 3-a lot of relief, 4-complete relief\]

Time frame:
Every two hours from baseline to 2 hours post dose
Reported as:
Mean · Units on a scale
SPRID at 2 Hours
Units on a scaleParacetamol Caplet 1000 mgParacetamol Caplet 500 mgPlacebo Caplet
SPRID at 2 Hours4.62 ± 3.313.26 ± 2.981.49 ± 2.54
SecondarySPRID at 4 Hours

SPRID:Sum of Pain Intensity Difference (SPID) and Total Pain Relief (TOTPAR) at each post-dosing time-point. SPRID score ranged from -3.8 (least pain relief) to 26.3 (highest pain relief). SPID and TOTPAR were calculated as weighted sums of Pain Intensity Differences (PID) and Pain Relief Scores (PRS) at each measurement time, respectively. PID was derived by subtracting the pain severity score at a given post-dosing time-point from the baseline \[pain severity score range:0-no pain, 1-mild pain, 2-moderate pain, 3-severe pain using a 4-point categorical Verbal Rating Scale (VRS)\]. If the subject rated pain intensity as 2 or 3, pain was assessed using a 100 mm Visual Analog Scale (VAS) \[0 (no pain), 100 (worst pain)\]. VAS scores were converted into PID scores by subtracting them from baseline pain scores. PRS was assessed on 5-point categorical pain relief rating scale \[0-no relief, 1-little relief, 2-some relief, 3-a lot of relief, 4-complete relief\]

Time frame:
Every two hours from baseline to 4 hours post dose
Reported as:
Mean · Units on a scale
SPRID at 4 Hours
Units on a scaleParacetamol Caplet 1000 mgParacetamol Caplet 500 mgPlacebo Caplet
SPRID at 4 Hours7.82 ± 7.364.42 ± 5.552.07 ± 5.45
SecondaryTotal Pain Relief (TOTPAR) at 2 Hours

TOTPAR was calculated as sum of products of pain relief (PR) at a given time-point (t) with the time-interval from that time-point to the previous time-point (t-1). The time-intervals used were 0-15, 15-30, 30-45, 45-60, 60-90, 90-120. Higher score indicated greater pain relief. TOTPARt = ∑PR x (timet - timet-1). PR score was assessed at each of the above time-points based on a 5-point categorical scale \[0-no relief, 1-little relief, 2-meaningful relief, 3-a lot of relief, 4-complete relief\].

Time frame:
Every two hours from baseline to 2 hours post dose
Reported as:
Mean · Units on a scale
Total Pain Relief (TOTPAR) at 2 Hours
Units on a scaleParacetamol Caplet 1000 mgParacetamol Caplet 500 mgPlacebo Caplet
Total Pain Relief (TOTPAR) at 2 Hours3.33 ± 1.982.46 ± 1.811.47 ± 1.53
SecondaryTOTPAR at 4 Hours

TOTPAR was calculated as sum of products of pain relief (PR) at a given time-point (t) with the time-interval from that time-point to the previous time-point (t-1). The time-intervals used were 0-15, 15-30, 30-45, 45-60, 60-90, 90-120, 120-240. Higher score indicated greater pain relief. TOTPARt = ∑PR x (timet - timet-1). PR score was assessed at each of the above time-points based on a 5-point categorical scale \[0-no relief, 1-little relief, 2-meaningful relief, 3-a lot of relief, 4-complete relief\].

Time frame:
Every two hours from baseline to 4 hours post dose
Reported as:
Mean · Units on a scale
TOTPAR at 4 Hours
Units on a scaleParacetamol Caplet 1000 mgParacetamol Caplet 500 mgPlacebo Caplet
TOTPAR at 4 Hours5.82 ± 4.373.73 ± 3.322.55 ± 3.15
SecondaryTOTPAR at 6 Hours

TOTPAR was calculated as sum of products of pain relief (PR) at a given time-point (t) with the time-interval from that time-point to the previous time-point (t-1). The time-intervals used were 0-15, 15-30, 30-45, 45-60, 60-90, 90-120, 120-240, 240-300 and 300-360. Higher score indicated greater pain relief. TOTPARt = ∑PR x (timet - timet-1). PR score was assessed at each of the above time-points based on a 5-point categorical scale \[0-no relief, 1-little relief, 2-meaningful relief, 3-a lot of relief, 4-complete relief\].

Time frame:
Every two hours from baseline to 6 hours post dose
Reported as:
Mean · Units on a scale
TOTPAR at 6 Hours
Units on a scaleParacetamol Caplet 1000 mgParacetamol Caplet 500 mgPlacebo Caplet
TOTPAR at 6 Hours8.05 ± 7.005.18 ± 5.444.10 ± 5.72
SecondarySum of Pain Intensity Difference (SPID) Scores at 2 Hours

SPID was calculated as sum of products of Pain Intensity Differences (PID) at a given time-point (t) with the time-interval from that time-point to the previous time-point (t-1). The time-intervals used were 0-15, 15-30, 30-45, 45-60, 60-90, 90-120. Positive and higher scores indicate greater reduction in pain. SPIDt = ∑PID x (timet - timet-1) Pain Intensity was assessed at baseline and at each time-point based on a 4-point categorical Verbal Rating Scale (VRS) scale: 0-no pain, 1-mild pain, 2-moderate pain, 3-severe pain. If the subject rated pain intensity as "2" or "3", pain was assessed using a 100 mm Visual Analog Scale (VAS) \[0 (no pain), 100 (worst pain)\]. VAS scores were converted into PID scores by subtracting them from pain scores taken at baseline.

Time frame:
Every two hours from baseline to 2 hours post dose
Reported as:
Mean · Units on a scale
Sum of Pain Intensity Difference (SPID) Scores at 2 Hours
Units on a scaleParacetamol Caplet 1000 mgParacetamol Caplet 500 mgPlacebo Caplet
Sum of Pain Intensity Difference (SPID) Scores at 2 Hours1.3 ± 1.50.8 ± 1.30.0 ± 1.2
SecondarySPID Scores at 4 Hours

SPID was calculated as sum of products of Pain Intensity Differences (PID) at a given time-point (t) with the time-interval from that time-point to the previous time-point (t-1). The time-intervals used were 0-15, 15-30, 30-45, 45-60, 60-90, 90-120, 120-240. Positive and higher scores indicate greater reduction in pain. SPIDt = ∑PID x (timet - timet-1) Pain Intensity was assessed at baseline and at each time-point based on a 4-point categorical Verbal Rating Scale (VRS) scale: 0-no pain, 1-mild pain, 2-moderate pain, 3-severe pain. If the subject rated pain intensity as "2" or "3", pain was assessed using a 100 mm Visual Analog Scale (VAS) \[0 (no pain), 100 (worst pain)\]. VAS scores were converted into PID scores by subtracting them from pain scores taken at baseline.

Time frame:
Every two hours from baseline to 4 hours post dose
Reported as:
Mean · Units on a scale
SPID Scores at 4 Hours
Units on a scaleParacetamol Caplet 1000 mgParacetamol Caplet 500 mgPlacebo Caplet
SPID Scores at 4 Hours2.0 ± 3.30.7 ± 2.6-0.5 ± 2.6
SecondarySPID Scores at 6 Hours

SPID was calculated as sum of products of Pain Intensity Differences (PID) at a given time-point (t) with the time-interval from that time-point to the previous time-point (t-1). The time-intervals used were 0-15, 15-30, 30-45, 45-60, 60-90, 90-120, 120-240, 240-300 and 300-360. Positive and higher scores indicate greater reduction in pain. SPIDt = ∑PID x (timet - timet-1) Pain Intensity was assessed at baseline and at each time-point based on a 4-point categorical Verbal Rating Scale (VRS) scale: 0-no pain, 1-mild pain, 2-moderate pain, 3-severe pain. If the subject rated pain intensity as "2" or "3", pain was assessed using a 100 mm Visual Analog Scale (VAS) \[0 (no pain), 100 (worst pain)\]. VAS scores were converted into PID scores by subtracting them from pain scores taken at baseline.

Time frame:
Every two hours from baseline to 6 hours post dose
Reported as:
Mean · Units on a scale
SPID Scores at 6 Hours
Units on a scaleParacetamol Caplet 1000 mgParacetamol Caplet 500 mgPlacebo Caplet
SPID Scores at 6 Hours2.6 ± 5.10.7 ± 4.1-0.8 ± 4.4
SecondaryParticipants Global Assessment to Response to Treatment (PGART)

PGART was measured by a score in a scale from 0-4: 0- Poor; 1- Fair 2- Good; 3- Very Good; 4- Excellent.

Time frame:
Baseline to 6 hours post dose
Reported as:
Mean · Units on a scale
Participants Global Assessment to Response to Treatment (PGART)
Units on a scaleParacetamol Caplet 1000 mgParacetamol Caplet 500 mgPlacebo Caplet
Participants Global Assessment to Response to Treatment (PGART)1.54 ± 1.201.24 ± 1.110.63 ± 0.92

Adverse events

Collected over All adverse events encountered or spontaneously reported following administration of any investigational product (including washout product), or for up to 5 days after the last administration of investigational product were recorded.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Paracetamol Caplet 1000 mg—0/121 (0%)32/121 (26.4%)
Paracetamol Caplet 500 mg—0/119 (0%)25/119 (21%)
Placebo Caplet—0/60 (0%)9/60 (15%)
Most frequent other events
Most frequent other events
EventParacetamol Caplet 1000 mgParacetamol Caplet 500 mgPlacebo Caplet
Alveolar OsteitisInfections and infestations20/12118/1193/60
HeadacheNervous system disorders12/1217/1196/60

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Paracetamol Caplet 1000 mgParacetamol Caplet 500 mgPlacebo CapletTotal
Mean24.0 ± 5.023.9 ± 3.923.5 ± 4.923.9 ± 4.5
Sex: Female, Male
Sex: Female, Male(Participants)Paracetamol Caplet 1000 mgParacetamol Caplet 500 mgPlacebo CapletTotal
Female687337178
Male534623122
Number of participants with pain severity score measured on a rating scale
Number of participants with pain severity score measured on a rating scale(Participants)Paracetamol Caplet 1000 mgParacetamol Caplet 500 mgPlacebo CapletTotal
Moderate979748242
Severe24221258
08

Study locations

2 sites
  • PPD Dental Clinic
    Austin, Texas 78744, United States
  • Jean Brown Research
    Salt Lake City, Utah 84124, United States
09

References and documents

Publications

  • Yue Y, Collaku A, Brown J, Buchanan WL, Reed K, Cooper SA, Otto J. Efficacy and speed of onset of pain relief of fast-dissolving paracetamol on postsurgical dental pain: two randomized, single-dose, double-blind, placebo-controlled clinical studies. Clin Ther. 2013 Sep;35(9):1306-20. doi: 10.1016/j.clinthera.2013.07.422. Epub 2013 Aug 22. PubMed 23972577 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2009, a primary completion of Mar 2010 and a completion of Mar 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2015, 4 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 18, 2010
First posted
Mar 8, 2010
Start
Oct 2009
Primary completionActual
Mar 2010
CompletionActual
Mar 2010
Results first posted
Jan 22, 2015
Last update
May 13, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 13, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01082081
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Mar 8, 2010
Start date
Oct 2009
Primary completion
Mar 2010
Completion
Mar 2010
Results posted
Jan 22, 2015
Last update
May 13, 2015

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Acetaminophen

Start the discussion